Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected stock price increase of over 20% relative to the benchmark index within the next six months [2][13]. Core Insights - The company reported a significant revenue increase of 44.2% year-on-year for the first three quarters of 2025, with total revenue reaching 276.0 billion yuan. The net profit attributable to shareholders was 11.4 billion yuan, a turnaround from a loss of 36.9 billion yuan in the same period last year [5][6]. - The global revenue for the drug Zebutinib surpassed 1 billion USD, with a notable growth of 53.2% in the first three quarters of 2025. The revenue breakdown shows strong performance in various regions, particularly in China, where it grew by 359% [6][9]. - The company has adjusted its full-year revenue guidance from 50-53 billion USD to 51-53 billion USD, while maintaining its guidance for positive GAAP operating profit [5][6]. Financial Performance Summary - For Q3 2025, the company achieved a revenue of 100.8 billion yuan, representing a 41.1% increase year-on-year. The gross margin for Q3 was reported at 85.9%, an increase of 3.1 percentage points compared to previous quarters [6][7]. - The projected revenues for 2025, 2026, and 2027 are 371.0 billion yuan, 471.5 billion yuan, and 581.8 billion yuan, respectively, with year-on-year growth rates of 36.3%, 27.1%, and 23.4% [9][11]. - The net profit attributable to shareholders is expected to reach 8.2 billion yuan in 2025, with a staggering growth of 116.5% compared to the previous year [9][11].

Core Insights - BeOne Medicines showcases its leadership in B-cell malignancies at the ASH 2025 conference, presenting extensive new data from its hematology portfolio, including BRUKINSA, sonrotoclax, and BGB-16673 [1][3][4] Group 1: BRUKINSA (Zanubrutinib) - BRUKINSA demonstrates sustained overall survival of 84% and 88% after COVID adjustment, with a landmark progression-free survival (PFS) superiority of 74% at 6 years in treatment-naïve chronic lymphocytic leukemia (CLL) [5] - Long-term data from the SEQUOIA and ALPINE studies confirm BRUKINSA's role as the backbone of CLL therapy, with continuous treatment showing clinically meaningful benefits [6][11] - BRUKINSA is positioned as the preferred BTK inhibitor due to its manageable side effect profile, including lower incidences of fatigue and pain compared to other treatments [8] Group 2: Sonrotoclax - Sonrotoclax, a next-generation BCL2 inhibitor, shows promising clinical activity in B-cell malignancies, with early trials indicating rapid undetectable minimal residual disease (uMRD) rates in treatment-naïve CLL patients [22][23] - The FDA has granted Breakthrough Therapy Designation for sonrotoclax in relapsed or refractory mantle cell lymphoma (MCL) and Fast Track Designation for MCL and Waldenström macroglobulinemia [24] Group 3: BGB-16673 - BGB-16673 is a potential first-in-class BTK protein degrader, with nearly 800 patients dosed in clinical trials, including three Phase 3 trials in relapsed/refractory CLL [25][26] - The drug is designed to degrade both wildtype and mutant forms of BTK, addressing resistance issues seen in patients with progressive disease [25] Group 4: Clinical Presentations and Data - Nearly 50 abstracts accepted for presentation at ASH 2025, including six oral presentations highlighting the efficacy and safety of BeOne's hematology assets [1][4] - Presentations will include real-world evidence and modeling approaches to refine understanding of treatment outcomes with BTK inhibitors [7][20] Group 5: Company Overview - BeOne Medicines is a global oncology company focused on developing innovative treatments for cancer, with a commitment to improving access to medicines for patients worldwide [32][33]

瑞士 001-37686 98-1209416 美国证券交易委员会 华盛顿特区 20549 _____________________ 8-K 表格 根据 1934 年证券交易法 第 13 或 15（d）条规定提交的 临时报告 报告日期（所报告最早事件之日期）：2025 年 11 月 13 日 百济神州有限公司 BEONE MEDICINES LTD. （注册人章程中列明的注册人准确名称） c/o BeOne Medicines I GmbH 94 Aeschengraben 27 Basel 4051 Switzerland （主要办事处地址）（邮政编码） +41 61 685 19 00 （注册地所在州或其他司法管辖区） （委员会档案编号） （国税局雇主识别号） 根据证券交易法第 12(b)条注册的证券： 各类别名称 交易代码 注册所在之各交易所名称 每股代表 13 股面值 0.0001 美元普通股之美国存托股 ONC 纳斯达克全球精选市场 每股面值 0.0001 美元之普通股* 06160 香港联合交易所有限公司 （注册人电话号码，包括区号） 不适用 （如自上一份报告起有改动，则为公司曾用名或原地址） ...

Core Viewpoint - The A-share market experienced fluctuations with the Sci-Tech Innovation Drug sector continuing to weaken, as evidenced by the Huatai-PineBridge Sci-Tech Innovation Drug ETF (589120) declining by 1.5% for four consecutive days, while still attracting over 13 million yuan in investments over the last two days [1][3][5]. Group 1: Market Performance - The Huatai-PineBridge Sci-Tech Innovation Drug ETF (589120) has seen a significant drop in its component stocks, with major companies like Rongchang Bio and Borui Pharma falling over 2%, while TeBao Bio and HaoYuan Pharma showed gains [3][4]. - The index for the Sci-Tech Innovation Drug ETF has had a remarkable year, with a peak increase of 98.84% as of September 5, reflecting the transformation of China's innovative drug industry over the past decade [5][6]. Group 2: Investment Trends - Despite the recent downturn, the ETF has managed to attract substantial capital, indicating ongoing investor interest in the sector [1][5]. - The market is currently in a performance vacuum following the earnings season, with rapid rotations observed, suggesting a trading-driven rather than a fundamental-driven adjustment in the innovative drug sector [5][8]. Group 3: Financial Performance - The innovative drug sector reported a revenue of 48.83 billion yuan for the first three quarters of 2025, marking a 22.1% increase, while the net profit showed a significant turnaround with a 147.1% increase in Q3 alone [8][10]. - The growth in revenue is attributed to the rapid commercialization of innovative drug products, increased sales, and milestone payments from licensing agreements [10]. Group 4: Future Outlook - The domestic innovative drug sector is witnessing a surge in overseas licensing deals, with 175 transactions amounting to over 104.2 billion USD, indicating a robust pipeline for future growth [7][8]. - The combination of policy support, innovation upgrades, and the normalization of overseas business development (BD) is expected to sustain high growth in the innovative drug sector [10].

Report Summary 1. Investment Rating The provided content does not mention the industry investment rating. 2. Core Views - Qi Zhen, a fund manager at Huabao Fund, has a "policy + industry" dual - driven investment framework, focusing on innovative drugs in the medium term. His investment style combines growth and certainty with flexible valuation tolerance, and he prefers long - term holding with low turnover and portfolio structure optimization [3][17][45]. - Since Qi Zhen took office, Huabao Big Health A has achieved remarkable returns, outperforming over 90% of similar pharmaceutical theme funds. Although its drawdown control is slightly weak, it still offers good risk - return performance [4][13][44]. - Qi Zhen is an excellent fund manager with a profound professional background, a mature investment system, and strict risk awareness. He is expected to continue generating excess returns as the Chinese innovative drug industry develops [46]. 3. Summary by Directory 3.1 Fund Manager Information - **Manager Introduction**: Qi Zhen holds a biotechnology bachelor's degree and a biology doctorate from Shanghai Jiao Tong University. He has worked in Northeast Securities and Essence Securities and joined Huabao Fund in October 2020. Since February 2023, he has been the fund manager of Huabao Big Health Hybrid Securities Investment Fund [4][9][44]. - **Managed Product Introduction** - **Representative Product**: Qi Zhen has managed Huabao Big Health A (006881.OF) since February 28, 2023. As of September 30, 2025, its total scale is 268 million yuan [4][10][44]. - **Representative Product Net Value Performance**: After excluding the 3 - month establishment period, Huabao Big Health A significantly outperformed the CSI All - Pharmaceutical Index, recording a cumulative positive excess return of 60.00%. Its return performance ranks among the top in pharmaceutical theme funds, surpassing over 90% of similar funds [11][13][15]. 3.2 Fund Manager Investment Ability Analysis - **Investment Scope - Policy + Industry Dual - Driven, Medium - Term Focus on Innovative Drugs**: Qi Zhen has a biological professional background and a large amount of professional reading. His investment framework is "policy + industry" dual - driven. He focuses on innovative drugs, with a position ratio of over 90%. He mines Alpha stocks with pipeline differentiation or expected inflection points and adjusts the portfolio dynamically [20][21][45]. - **Stock - Holding Characteristics - Balancing Growth and Certainty, Flexible Valuation Tolerance**: For innovative drug companies, Qi Zhen uses pipeline market value conversion for valuation, considering factors such as clinical stage success rate and management credibility. He gives higher valuation space to innovative drugs and focuses more on static valuation and performance improvement in traditional sub - industries [29][45]. - **Operation Characteristics - Preference for Long - Term Holding, Low Turnover, and Portfolio Structure Optimization**: Qi Zhen's operation strategy is mainly long - term holding of core positions, with an annualized turnover rate of only 2 - 3 times. He prefers to invest when the stock price is at the bottom or oversold. He controls drawdown by adjusting the portfolio structure rather than market timing and shows flexibility in A/H share allocation [35][36][45]. 3.3 Summary - Qi Zhen is an outstanding fund manager with a "policy + industry" analysis framework, pipeline market value valuation method, and multi - level risk control system. He is expected to create excess returns as the Chinese innovative drug industry develops. Investors can allocate his products to participate in the investment opportunities of the Chinese pharmaceutical industry upgrade [46]. 3.4 Appendix - The appendix provides product elements of Huabao Big Health A, including fund name, abbreviation, full name, establishment date, comparison benchmark, investment target, investment scope, management fee rate, and current fund manager's tenure [48].

Investment Rating - The industry investment rating is "Recommended (Maintain)" [1] Core Views - The innovative drug industry chain continues to show strong performance, with the pharmaceutical and biotechnology sector outperforming the CSI 300 index, rising by 3.29% while the index fell by 1.08% during the week of November 10 to November 14, 2025 [9][10] - The market potential for small nucleic acids is continuously increasing, indicating that it may become a significant technological hotspot in innovative drugs [19][22] - The sentiment in the innovative drug sector has recently declined, but the sustainability of the sector's prosperity is expected to continue, with a focus on "innovation + internationalization" [22][24] Summary by Sections 1. Weekly Pharmaceutical Sector Performance - The pharmaceutical and biotechnology sector has shown a year-to-date increase of 22.99%, outperforming the CSI 300 index by 5.38 percentage points [9] - The sector's valuation as of November 14, 2025, is 30.89 (PE, TTM), with a premium of 129.74% over the CSI 300 index [10] 2. Industry Events/Policy Overview - On November 14, 2025, the National Bureau of Statistics reported a stable economic performance, with industrial production increasing by 4.9% year-on-year [17] - The People's Bank of China reported an increase of 14.97 trillion yuan in RMB loans in the first ten months of 2025 [17] 3. Industry Investment Strategy - The report highlights the active business development (BD) transactions in the innovative drug sector, with significant collaborations and licensing agreements, such as the partnership between Sainty Biotech and Eli Lilly [19] - The report suggests a focus on the recovery of the medical device and traditional Chinese medicine sectors, as well as the ongoing improvement in the innovative drug industry chain [22][28] 4. Recommended Stocks - Recommended stocks include: - **Hengrui Medicine**: Expected to achieve rapid growth in both domestic and international markets [29] - **BeiGene**: Anticipated to achieve comprehensive profitability in 2025, with strong performance in its core products [30] - **Innovent Biologics**: Expected to reach a revenue target of 20 billion yuan by 2027 [31] - **Kanglong Chemical**: Projected to see significant revenue growth driven by its innovative products [32] - **WuXi AppTec**: Anticipated to maintain rapid growth in its core business and increase global production capacity [33]

Core Viewpoint - Major investment banks like UBS and Goldman Sachs are optimistic about the performance of the Chinese market in 2026, highlighting opportunities in sectors such as AI and overseas expansion [1][7]. Group 1: Market Performance and Trends - The A-share market has experienced fluctuations, with the Shanghai Composite Index closing at 3939.81 points on November 18, down 0.81% [2]. - Despite market volatility, foreign investment interest remains high, with over 100 A-share companies receiving foreign research attention this month [2][4]. - The overall health of corporate earnings, supported by robust Q3 reports, indicates that recent market fluctuations are more influenced by sentiment rather than fundamental weaknesses [6]. Group 2: Foreign Investment and Research - AI companies are the most favored by foreign investors, with Optoelectronics receiving 92 institutional research visits, over half from foreign entities [2][3]. - Other notable companies attracting foreign research include BeiGene, Luxshare Precision, and Huichuan Technology, all of which are involved in AI or technology sectors [4][5]. - The trend shows that large-cap stocks continue to attract foreign interest, with companies like Wens Foodstuffs, Industrial Fulian, and BYD being included in recent foreign research lists [4]. Group 3: Future Outlook and Investment Themes - UBS forecasts that the Chinese stock market will experience another prosperous year in 2026, driven by innovation, particularly in AI, and supportive policies for private enterprises [7]. - Key investment themes identified by UBS include internet, hardware technology, and brokerage sectors, while high-dividend stocks are being deprioritized [7]. - Goldman Sachs also highlights several investment themes expected to outperform the market, including the return of private enterprises, overseas expansion, and AI-related sectors [7].

Group 1 - Overseas institutions conducted research on 84 listed companies in the past 10 days, with Optoelectronics being the most focused, receiving attention from 58 overseas institutions [1] - A total of 437 companies were researched by institutions, with securities companies leading at 395, followed by fund companies at 301 [1] - The average stock price of companies researched by overseas institutions increased by 1.33% over the past 10 days, with the best performer being Huasheng Lithium with a cumulative increase of 121.01% [1] Group 2 - The second most researched company was BeiGene, which had 43 overseas institutions participating in its research [1] - Among the stocks that experienced price declines, Lingzhi Software had the largest drop at 14.58% [3] - The research highlighted various sectors, including power equipment, electronics, and machinery, with notable stock performances across these industries [1][2][3]

Group 1: Report Summary - The report analyzes the investment value of Zhang Jintao, a fund manager at Huabao Fund, with a focus on his performance in managing Huabao Pharmaceutical Biology A [1][4]. - Zhang Jintao has developed an investment methodology that combines industry cycle analysis with a multi - dimensional framework, showing strong adaptability in the current era of global opportunities for Chinese innovative drugs [5][20]. - Since Zhang Jintao took office, Huabao Pharmaceutical Biology A has achieved above - average returns among pharmaceutical theme funds, outperforming nearly 80% of its peers, with relatively strong offensive capabilities [4][16]. Group 2: Fund Manager Information 2.1 Fund Manager Introduction - Zhang Jintao has worked in multiple financial institutions, including Huatai United Securities, ABC Fortune Fund, etc. He joined Huabao Fund in April 2021 and has served as the fund manager of multiple funds since May 2021 [4][10]. 2.2 Management Product Introduction 2.2.1 Representative Product - Zhang Jintao has managed Huabao Pharmaceutical Biology A (240020.OF) since May 7, 2021, with a total scale of 629 million yuan as of September 30, 2025 [11]. 2.2.2 Representative Product Net Value Performance - After Zhang Jintao took office, excluding the 3 - month construction period, Huabao Pharmaceutical Biology A significantly outperformed the All - Index Pharmaceutical Index, achieving a cumulative positive excess return of 40.27% [12]. - In terms of performance among peers, it ranks in the upper - middle position, but its risk - control indicators such as volatility are relatively weak. Overall, it still has good cost - effectiveness [16]. Group 3: Fund Manager Investment Ability Analysis 3.1 Investment Scope - Guided by Industry Cycle and Anchored by Market Value Space - Zhang Jintao's investment system is based on a deep understanding of the "five - year cycle" of the pharmaceutical industry. He believes that the Chinese innovative drug industry has entered the stage of results realization after a long - term R & D investment period [21]. - He has constructed a "policy - industry - valuation" three - dimensional decision - making framework. The policy dimension focuses on understanding policy intentions; the industry dimension focuses on verifying industry and company fundamentals; the valuation dimension calculates the long - term target market value to evaluate risk - return ratios [21][22]. 3.2 Holding Characteristics - Portfolio Construction Highlights Industry Thinking - Zhang Jintao highly concentrates on the innovative drug sector, aiming to obtain alpha returns within the innovative drug industry by focusing on companies with upcoming blockbuster products or in the rapid - volume - growth stage [20][30]. - He also strategically allocates about 8% of the portfolio to the CXO sector as a supplement and risk - hedge. His average holding period is about 1 - 2 years, and he emphasizes dynamic adjustment [30]. 3.3 Operational Characteristics - Keeping Pace with the Times and Dynamically Optimizing - Zhang Jintao maintains a high stock position, believing that it is difficult to obtain excess returns through position timing in the pharmaceutical industry. Instead, he focuses on stock selection [35]. - The portfolio's turnover mainly comes from the optimization of non - core positions. The top ten heavy - holding stocks remain relatively stable, while the tail positions are adjusted more frequently to track new industry trends [35]. - The holding concentration is adjusted dynamically according to the industry stage, with a relatively dispersed strategy in the early stage and a gradually increasing concentration as the industry trend becomes clearer [35]. Group 4: Conclusion - Zhang Jintao's investment methodology combines industry - level strategic judgment with individual - stock tactical selection, showing strong adaptability and viability in the context of the global opportunities for Chinese innovative drugs [45][46]. - Huabao Pharmaceutical Biology A, under his management, has achieved good performance among pharmaceutical theme funds, with relatively strong offensive capabilities but slightly weaker defensiveness [44].

Core Insights - The Sci-Tech Innovation Board (STAR Market) has become a key indicator of the performance and development trends of "hard technology" enterprises in China, with significant growth in R&D investment and net profit [1][2]. Group 1: Performance Metrics - As of November 13, 592 companies on the STAR Market reported a total R&D investment of nearly 120 billion yuan and total revenue exceeding 1.1 trillion yuan for the first three quarters, with a net profit growth of 75% year-on-year in Q3 [1]. - For the first three quarters of 2025, STAR Market companies achieved a revenue of 1,105 billion yuan, a year-on-year increase of 7.9%, and a net profit of 49.27 billion yuan, up 8.9% year-on-year [2]. - Over 70% of STAR Market companies reported revenue growth, and nearly 60% reported net profit growth, with 158 companies seeing net profit increases exceeding 50% [2]. Group 2: R&D Investment - The total R&D investment for STAR Market companies reached 119.75 billion yuan, which is 2.4 times the net profit, with a median R&D intensity of 12.4%, leading all A-share sectors [4]. - The "1+6" reform initiated in June aims to support unprofitable tech companies, with 35 such companies showing promising development by prioritizing R&D [4]. Group 3: Sector Performance - The integrated circuit sector saw 121 related companies on the STAR Market achieve a revenue growth of 25% and a net profit growth of 67% in the first three quarters [6]. - The artificial intelligence sector has emerged as a new growth pillar, with companies like Cambrian and Haiguang Information reporting revenue increases of nearly 24 times and 55%, respectively [6]. - The biopharmaceutical sector experienced a revenue growth of 11% and a net profit growth of 48%, with nine new drugs approved for market and significant international business development [7].